Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHV370 in Sjögren's Syndrome and MCTD
NCT04988087Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of MHV370 in Sjögren's syndrome, mixed connective tissue disease (MCTD), sponsored by Novartis. Started Nov 2021; status: terminated.
02
Drugs
MHV370
03
Conditions
Sjögren's syndromemixed connective tissue disease (MCTD)
Beyond the preview
Go deeper on NCT04988087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988087.